GSA Capital Partners’s Arbutus Biopharma ABUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.65M Buy
344,290
+300,208
+681% +$1.45M 0.1% 266
2026
Q2
$212K Buy
+44,082
New +$194K 0.01% 1493
2023
Q3
– Sell
-36,923
Closed -$85K – 1443
2023
Q2
$85K Sell
36,923
-1,237
-3% -$3.22K 0.01% 1391
2023
Q1
$116K Sell
38,160
-79,031
-67% -$223K 0.01% 1337
2022
Q4
$273K Buy
117,191
+22,391
+24% +$53.6K 0.03% 999
2022
Q3
$181K Buy
94,800
+78,664
+488% +$185K 0.02% 1258
2022
Q2
$44K Sell
16,136
-16,317
-50% -$41.8K 0.01% 1297
2022
Q1
$97K Buy
+32,453
New +$99.3K 0.01% 1298
2021
Q2
– Sell
-309,839
Closed -$1.03M – 1285
2021
Q1
$1.03M Buy
309,839
+283,618
+1,082% +$1.09M 0.17% 125
2020
Q4
$93K Buy
+26,221
New +$91.8K 0.02% 1103

Other funds holding ABUS

GSA Capital Partners's ABUS Position: Q3 2026 in Review

GSA Capital Partners increased its Arbutus Biopharma (ABUS) stake by 681% in Q3 2026, buying an estimated $1.45M and bringing the position to 344,290 shares worth $1.65M. The position accounts for 0.1% of the portfolio, ranked #266.

GSA Capital Partners first reported a position in ABUS in Q4 2020 and has held it in 10 quarters since. 216 funds tracked by Wall St. Rank hold ABUS as of Q3 2026.

  • GSA Capital Partners held 344,290 shares of Arbutus Biopharma worth $1.65M as of Q3 2026.
  • GSA Capital Partners bought 300,208 Arbutus Biopharma shares in Q3 2026, an estimated $1.45M.
  • Arbutus Biopharma made up 0.1% of GSA Capital Partners's portfolio in Q3 2026, its #266 holding.
  • GSA Capital Partners first reported a position in Arbutus Biopharma in Q4 2020 and has held it in 10 quarters since.
  • 216 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2026.

Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.